{"slideshow_credits": null, "snippet": "Esbriet and Ofev do not make patients better, but slow the rate at which lung function declines.", "abstract": "Drugs Esbriet from Roche and Ofey from Boehringer Ingelheim win approval from Food and Drug Administration, and are the first that can slow progression of idiopathic pulmonary fibrosis; FDA approval could open new era for patients but also a new chapter in controversy over high drug prices.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/10/16/business/fda-approves-first-2-drugs-for-treatment-of-a-fatal-lung-disease.html", "lead_paragraph": "Esbriet and Ofev do not make patients better, but slow the rate at which lung function declines.", "headline": {"main": "F.D.A. Approves First 2 Drugs for Treatment of a Fatal Lung Disease ", "print_headline": "F.D.A. Approves First 2 Drugs for Treatment of a Fatal Lung Disease"}, "_id": "543f176038f0d853e89f69df", "word_count": "696", "multimedia": [{"height": 126, "url": "images/2014/10/16/business/Drug/Drug-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/10/16/business/Drug/Drug-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 833, "url": "images/2014/10/16/business/Drug/Drug-articleLarge.jpg", "legacy": {"xlarge": "images/2014/10/16/business/Drug/Drug-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "833"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/10/16/business/Drug/Drug-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/10/16/business/Drug/Drug-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-10-16T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Respiratory System", "name": "subject", "is_major": "N", "rank": "11"}, {"value": "Roche Holding AG", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Boehringer Ingelheim GmbH", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Idiopathic Pulmonary Fibrosis", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Lungs", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "is_major": "N", "rank": "9"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "10"}], "blog": [], "subsection_name": null, "type_of_material": "News"}